Daihan Pharmaceutical Co.,Ltd.

KOSDAQ:A023910 Stok Raporu

Piyasa değeri: ₩148.8b

Daihan PharmaceuticalLtd Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Daihan PharmaceuticalLtd has been growing earnings at an average annual rate of 2.4%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 4.2% per year. Daihan PharmaceuticalLtd's return on equity is 11.6%, and it has net margins of 15.2%.

Anahtar bilgiler

2.4%

Kazanç büyüme oranı

2.8%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi11.3%
Gelir büyüme oranı4.2%
Özkaynak getirisi11.6%
Net Marj15.2%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Here's Why Daihan PharmaceuticalLtd (KOSDAQ:023910) Can Manage Its Debt Responsibly

Mar 02
Here's Why Daihan PharmaceuticalLtd (KOSDAQ:023910) Can Manage Its Debt Responsibly

Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Feb 09
Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Can You Imagine How Daihan PharmaceuticalLtd's (KOSDAQ:023910) Shareholders Feel About The 34% Share Price Increase?

Jan 19
Can You Imagine How Daihan PharmaceuticalLtd's (KOSDAQ:023910) Shareholders Feel About The 34% Share Price Increase?

What Kind Of Shareholders Hold The Majority In Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Shares?

Dec 18
What Kind Of Shareholders Hold The Majority In Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Shares?

Does Daihan PharmaceuticalLtd (KOSDAQ:023910) Have A Healthy Balance Sheet?

Nov 27
Does Daihan PharmaceuticalLtd (KOSDAQ:023910) Have A Healthy Balance Sheet?

Gelir ve Gider Dağılımı

Daihan PharmaceuticalLtd nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

KOSDAQ:A023910 Gelir, gider ve kazançlar (KRW Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 24198,05230,03627,7732,097
31 Mar 24198,83429,38427,3381,805
31 Dec 23195,91128,42626,9561,641
30 Sep 23194,52826,21126,6541,425
30 Jun 23192,25926,52126,207617
31 Mar 23189,04326,08925,994607
31 Dec 22184,26824,96125,411568
30 Sep 22181,12226,19725,482556
30 Jun 22177,12625,02925,050476
31 Mar 22173,72623,69024,985586
31 Dec 21171,46322,67024,781791
30 Sep 21166,61916,68024,212977
30 Jun 21165,49516,16624,3621,035
31 Mar 21162,37215,56824,471909
31 Dec 20166,08017,38124,573689
30 Sep 20170,11626,24625,185384
30 Jun 20170,01126,43824,809396
31 Mar 20172,49228,70224,345393
31 Dec 19168,76228,16724,237392
30 Sep 19165,17827,40823,217494
30 Jun 19161,92627,61823,535476
31 Mar 19158,29828,25622,363467
31 Dec 18158,72028,51822,747458
30 Sep 18153,40226,63121,909431
30 Jun 18152,13027,44921,857409
31 Mar 18149,08326,14822,383397
31 Dec 17144,43924,83221,427382
30 Sep 17145,31923,70221,863394
30 Jun 17140,74321,18321,021393
31 Mar 17140,07718,88120,847394
31 Dec 16139,43717,65720,688410
30 Sep 16134,84316,85320,510403
30 Jun 16131,99415,77420,249397
31 Mar 16128,84515,28520,033461
31 Dec 15124,27613,77620,002356
30 Sep 15121,29612,27520,082257
30 Jun 15118,69811,12620,292212
31 Mar 15114,7399,81720,05168
31 Dec 14111,70910,42019,44568
30 Sep 14109,61010,00018,340114
30 Jun 14107,8347,92417,72982
31 Mar 14107,2298,30517,20861
31 Dec 13106,8037,77116,85992

Kaliteli Kazançlar: A023910 has high quality earnings.

Büyüyen Kar Marjı: A023910's current net profit margins (15.2%) are higher than last year (13.8%).


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: A023910's earnings have grown by 2.4% per year over the past 5 years.

Büyüme Hızlandırma: A023910's earnings growth over the past year (13.3%) exceeds its 5-year average (2.4% per year).

Kazançlar vs. Sektör: A023910 earnings growth over the past year (13.3%) did not outperform the Pharmaceuticals industry 21.9%.


Özkaynak Getirisi

Yüksek ROE: A023910's Return on Equity (11.6%) is considered low.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin